Phase 3 trial of trofinetide in Rett syndrome commences
Filed with ASX · · 4 pages · English
Neuren Pharmaceuticals Limited on 6ix
Story so far
Earlier from Neuren Pharmaceuticals
- FDA Grants Orphan Drug Designation for Neuren's NNZ-2591 to Treat Angelman, Phelan-McDermid and Pitt Hopkins Syndromes
- FDA grants Orphan for both Phelan-McDermid and Pitt Hopkins
- FDA grants Orphan Drug Designation for NNZ-2591 in Angelman
- Neuren approaching key milestones in Q4 2019
- NNZ-2591 positive effects in Pitt Hopkins syndrome model
Later from Neuren Pharmaceuticals
- Patent to 2034 granted in Europe for Neurens NNZ-2591
- 2019 year-end update and 2020 outlook
- Update on trofinetide Phase 3 trial in Rett syndrome
- Appendix 4E and 2019 full year accounts
- Rare Pediatric Disease designation received from FDA
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals